ReviewFrontiers in endocrinology2026
Will GLP-1-based therapies reshape the epidemiology of MASLD? An emerging public health perspective.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease worldwide, driven by increasing obesity and type 2 diabetes mellitus. The expanding use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) raises an epidemiological question: could therapies targeting these metabolic drivers reshape the future burden of chronic liver disease? GLP-1-based therapies reduce body weight and improve metabolic dysfunction, with potential implications for hepatic steatosis and disease progression. The phase 3 ESSENCE trial demonstrated histological benefits of semaglutide in metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced fibrosis, supporting accelerated or conditional regulatory approvals. However, effects on liver-related clinical outcomes remain unproven. In this Perspective, we examine the evidence and translate it into an explicitly parameterized scenario using a potential impact fraction. Combining published estimates of eligibility, relative risk, treatment persistence, and effectiveness with coverage scenarios of 5%, 10%, and 20%, the model suggests relative reductions of approximately 0.3% to 1.1% in the global incidence of cirrhosis among individuals with prevalent MASLD, at equilibrium (95% uncertainty interval at 20% coverage and intermediate persistence, 0.6% to 1.6%; best-case envelope, 4.6%). These estimates represent testable hypotheses rather than established clinical effects. Effective coverage, defined as coverage multiplied by persistence, is the principal constraint. We identify observations that would refute these expectations and discuss implications for prevention, healthcare systems, and the natural history of MASLD. Population benefits will depend on sustained treatment, accessibility, affordability, and equitable implementation, alongside confirmation that histological improvements translate into fewer liver-related clinical events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.